Online inquiry

IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2396MR)

This product GTTS-WQ2396MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&EPCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_000733.4; NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 4072
UniProt ID P07766; P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2396MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9667MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ1657MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACT-017
GTTS-WQ14911MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ513MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ1410MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ11422MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ141MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ6028MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 1275
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW